US-based mutual insurance company Sham has helped Alizé Pharma, a France-based metabolic diseases and cancer group, raise €3.3m ($4.1m). The round was joined by Octalfa, a family office, Cema Inc, a Canada-based holding company, and Thierry Abribat, Alizé’s founder and president. In 2009 Sham, Octalfa and Cema invested in a €3m round, taking the amount…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
